Navigation Links
Lexicon To Present At The Wedbush PacGrow Life Sciences Management Access Conference
Date:8/7/2013

THE WOODLANDS, Texas, Aug. 7, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Wedbush PacGrow Life Sciences Management Access Conference on Tuesday, August 13, at 1:20 PM ET in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.

A webcast of the presentation will be available through Lexicon´s website at www.lexpharma.com. An archived version of the presentation will be available at www.lexpharma.com until September 13, 2013.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on managem
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Second Quarter Financial Results
2. Lexicon to Report Second Quarter Financial Results on July 30, 2013
3. Lexicon Presents Data at the American Diabetes Association Meeting On Blood Pressure Reduction and Weight Loss In Clinical Trial of LX4211
4. Lexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose Absorption From Gastrointestinal Tract
5. Lexicon To Present At The Goldman Sachs Global Healthcare Conference
6. Lexicon To Present At The Jefferies Global Healthcare Conference
7. Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial Results
9. Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
10. Lexicon to Report First Quarter Financial Results on May 10, 2013
11. Lexicon To Present At The Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 According ... Product & Services (Equipment, Reagent, Primer, Probe, Custom ... PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) - ... global Oligonucleotide Synthesis Market is expected to reach ... 2014, growing at a CAGR of 9.8% from ...
(Date:8/29/2014)... 2014 Research and Markets has ... Drugs Market 2014-2018" report to their offering. ... condition that results in demyelination, axonal transection, and neurodegeneration. ... response by the immune system, which targets neurons within ... debilitating disease in which the damage of the myelin ...
(Date:8/29/2014)... British Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the ... fiscal year-end financial statements.  The Company recently changed its ... facilitate an application to list its common stock on ... DelMar,s financial statements as filed with the ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... Phreesia, the patient check-in company, today announced that ... (EHR) software and solutions, has been named a ... practices nationwide that use both SOAPware and Phreesia ... check-in experience. The automated interface between the two ...
... QUINCY, Mass., Oct. 18, 2011 For thousands of nurses, ... the challenge of shopping for the latest in scrub fashions ... Building on the success of the 10 original stores ... now set to open in Tampa, Orlando and Miami FL; ...
Cached Medicine Technology:Phreesia and SOAPware Integrate to Improve Clinical Data and Streamline Workflow at Medical Practices 2Phreesia and SOAPware Integrate to Improve Clinical Data and Streamline Workflow at Medical Practices 3An RX for Busy Healthcare Professionals 2An RX for Busy Healthcare Professionals 3
(Date:8/29/2014)... UWDress.com, one of the most famous dress ... of 2014 floor length bridesmaid dresses . Additionally, ... items. According to the company’s marketing specialist, all its ... rate (up to 60 percent off) before September 10. ... special neckline: strapless, one-shoulder, bateau and more. The main ...
(Date:8/29/2014)... to new research presented in a Science Daily article entitled ... Misuse Among Young Adults (8/16), peer pressure should not ... comes to prescription drug abuse. Researchers from Purdue University have ... which influences misuse of prescription drugs is access to friends ... have fun with other using friends. Evidently there is not ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe is ... G. Rodas. Dr. Rodas will be practicing out of ... As a member of Healthpointe’s orthopedic team, ... internal medicine, and board-certified in occupational medicine. , ... title as Medical Director of Raytheon, the world-class defense ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Highly regarded audiologist ... on important hearing health topics. The four reports are titled:, ... The Secrets to Hearing Aid Success , The Top ... Understanding Auditory Processing Disorder in Children , ... because there is a lot of confusion and misinformation about each ...
(Date:8/29/2014)... Healthpointe Medical Group, one of Southern ... from LAXMed. The medical center is less than 2 miles ... of the 405 freeway. , The LAX clinic marks ... center is located at: 8610 S. Sepulveda Blvd., Suite 204 ... LAX office will provide the same comprehensive services as ...
Breaking Medicine News(10 mins):Health News:2014 Floor Length Bridesmaid Dresses for Sale at UWDress.com 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 3Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 3Health News:Healthpointe Obtains a New Medical Clinic in the LAX Area 2
... , TUESDAY, Jan. 12 (HealthDay News) -- An experimental ... study shows. , The drug, DBZ, currently in clinical ... have side effects on the lining of the lower ... to those seen in Barrett,s esophagus, a condition that ...
... two ,good, copies slows age-linked mental decline by half, study ... variant that is good for the heart also appears to ... function and cutting the odds for Alzheimer,s disease, a study ... form of the gene, it reduces the risk of Alzheimer,s ...
... ... and Normal Lives Due to Groundbreaking Gene Therapy, , ... Cambridge, MA (Vocus) January 12, 2010 -- Genetix Pharmaceuticals, a leader ... ALD gene therapy research recently published by its collaboratiors at National Institute of Health and ...
... , WATERTOWN, Mass. , Jan. 12 ... cardiovascular system is also good for the brain, according to ... been braving cold temperatures to get in shape for the ... are encouraging others to keep in shape as well. , ...
... 5, 2010An enzyme that normally helps break down stored ... them more malignant, according to new findings by a ... has focused on the mechanisms leading to cancer formation ... says Benjamin Cravatt, chair of the Scripps Research Department ...
... , , SHENZHEN, China , ... www.htdsmedical.com ) announced that its directors have resolved that up ... sale of its MindUp division to Hiru will be distributed to ... Terry Yuan , HTDS President, said, "In our efforts to maximize ...
Cached Medicine News:Health News:Gene Variant Could Lower Alzheimer's Risk 2Health News:Gene Variant Could Lower Alzheimer's Risk 3Health News:Genetix Pharmaceuticals' Adrenoleukodystrophy (ALD) Product Recognized As One of Science Magazine's Top 10 Scientific Breakthroughs of 2009 2Health News:Genetix Pharmaceuticals' Adrenoleukodystrophy (ALD) Product Recognized As One of Science Magazine's Top 10 Scientific Breakthroughs of 2009 3Health News:The Run for the Memory Marathon Team Getting in Shape and Fighting Alzheimer's 2Health News:The Run for the Memory Marathon Team Getting in Shape and Fighting Alzheimer's 3Health News:The Run for the Memory Marathon Team Getting in Shape and Fighting Alzheimer's 4Health News:Scripps Research scientists find cancer cells co-opt fat metabolism pathway to become more malignant 2Health News:Scripps Research scientists find cancer cells co-opt fat metabolism pathway to become more malignant 3Health News:Hard To Treat Diseases (HTDS) To Disperse Special One Time Hiru (HIRU) Common Stock 2Health News:Hard To Treat Diseases (HTDS) To Disperse Special One Time Hiru (HIRU) Common Stock 3Health News:Hard To Treat Diseases (HTDS) To Disperse Special One Time Hiru (HIRU) Common Stock 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: